Instrument Inactif

Autres langues Mount Magnet South Ltd Australian S.E.

Actions

AU000000MUM1

Recherche biotechnologique et médicale

Cours en clôture Australian S.E. Autres places de cotation
- ^AUD	-

25/06	Incannex Healthcare Inc obtient un brevet aux États-Unis pour l'IHL-42X dans le traitement de l'apnée obstructive du sommeil	CI
25/06	Incannex Healthcare obtient un brevet américain pour l'IHL-42X dans le traitement de l'apnée obstructive du sommeil	MT

Autres langues

25/06	Incannex Healthcare Inc Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
25/06	Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea
25/06	Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
10/06	Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
09/06	Incannex Announces Initiation of Research Coverage by Alliance Global Partners
15/05	Tranche Update on Incannex Healthcare Inc.'s Equity Buyback Plan announced on August 22, 2025.
15/05	Incannex Healthcare Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026
14/05	Incannex Healthcare commences Dreamzz clinical study of IHL-42X for obstructive sleep apnea
14/05	Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
14/05	Incannex Healthcare Inc Commences DReAMzz Clinical Study For IHL-42X In Obstructive Sleep Apnea
12/05	Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
22/04	Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness
22/04	Incannex Healthcare Inc. Announces Incannex?s Completed Phase 2 Clinical Trial, PSX-001 Demonstrated Statistically Significant and Clinically Meaningful Improvements Across All Primary and Secondary Endpoints
27/03	Incannex reactivates share repurchase program, underscoring confidence in valuation and strategic position
27/03	Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position
25/03	Incannex Healthcare Inc. Enters Partnership Agreement with American Academy of Sleep Medicine Foundation
25/03	Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research
18/03	Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development
17/03	Incannex regains compliance with Nasdaq minimum bid price requirement
17/03	Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement
12/03	Incannex Healthcare Inc. Strengthens Clinical Development Pathway For IHL-42X Following Positive Phase 2 Outcomes
12/03	Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
12/03	Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes
25/02	Incannex Healthcare approved 1-for-30 reverse stock split
25/02	Incannex Announces Reverse Stock Split